IP40 Stock Chart & Stats
€1.50
€0.00(0.00%)
At close: 4:00 PM EDT
€1.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.39 - €13.20
Previous CloseN/A
Volume0.00
Average Volume (3M)913.00
Market Cap
€6.09M
Enterprise Value€4.95M
Total Cash (Recent Filing)€6.68M
Total Debt (Recent Filing)€1.42M
Price to Earnings (P/E)―
Beta-0.34
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding4,498,772
10 Day Avg. Volume1,148
30 Day Avg. Volume913
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginVery high gross margin (~90%) indicates the company’s core cannabinoid formulations and delivery tech have favorable unit economics. Sustained high gross margins provide flexibility to invest in R&D and commercialization, and can support long-term profitability if operating expenses are controlled.
Moderate Leverage / Solid Equity BaseModerate leverage and a meaningful equity base give InnoCan flexibility to fund ongoing development and absorb near-term volatility. Structurally, a debt-to-equity around 0.27 provides room to finance R&D or commercialization without immediate solvency pressure, assuming losses are managed.
Niche Product & Proprietary Delivery TechA focused strategy on cannabinoid medicines and proprietary long-acting/controlled-release delivery creates structural differentiation. IP-backed delivery platforms and addressing both human and veterinary markets diversify potential revenue paths and support sustained competitive advantage.
Bears Say
Negative Cash Flow / Cash BurnTTM negative operating and free cash flow show renewed cash burn after prior positive results. Persistent negative cash conversion raises reliance on external financing or cost cuts, increasing dilution or leverage risk and constraining the firm’s ability to execute multi‑period development plans.
Revenue Contraction / Slowing GrowthA TTM revenue decline after prior multi‑year growth signals that top-line momentum has stalled. Slowing revenue undermines scale economics, makes fixed costs harder to absorb, and lengthens the path to sustainable profitability absent meaningful commercial or product traction.
Unprofitable With Negative ReturnsNet margin around -6% and negative operating profit mean the company remains loss‑making despite very high gross margins. Negative returns on equity indicate capital is not generating profits, implying operating expense structure or scale inefficiencies must be corrected for durable profitability.
InnoCan Pharma News
IP40 FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was €1.39 and its highest was €13.20 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is €6.09M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Aug 31, 2026 which is in 31 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on May 27, 2026. The company reported -€0.184 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.184.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -€0.184 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 27.647%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in DE:IP40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Voyageur Pharmaceuticals
―
Avicanna
―